{"transactions":[{"id":767626,"issuer":{"id":4007,"kind":"organization","name":"Envista Holdings Corp"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T20:37:09.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":9330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of an annual equity grant of Restricted Stock Units (\"RSUs\") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the first anniversary of the grant date. RSUs are payable in shares of common stock on a one-to-one basis."}],"balance_after":54010,"source":{"system":"sec-edgar","filing":"0001308428-26-000003","document":"wk-form4_1779395827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1308428/000130842826000003/wk-form4_1779395827.xml","form_type":"4"}},{"id":787489,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-09T01:17:34.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":1064,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This restricted stock award was granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders."}],"balance_after":4315,"source":{"system":"sec-edgar","filing":"0001225208-26-005050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520826005050/doc4.xml","form_type":"4"}},{"id":787488,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-09T01:17:34.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":3251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders."}],"balance_after":3251,"source":{"system":"sec-edgar","filing":"0001225208-26-005050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520826005050/doc4.xml","form_type":"4"}},{"id":1113034,"issuer":{"id":4007,"kind":"organization","name":"Envista Holdings Corp"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-12T20:55:53.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":10450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of an annual equity grant of Restricted Stock Units (\"RSUs\") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the first anniversary of the grant date. RSUs are payable in shares of common stock on a one-to-one basis."}],"balance_after":44680,"source":{"system":"sec-edgar","filing":"0001628280-25-031069","document":"wk-form4_1749761747.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1308428/000162828025031069/wk-form4_1749761747.xml","form_type":"4"}},{"id":1154333,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-09T23:57:42.000Z","date":"2025-05-09","kind":"grant","planned":false,"acquired":true,"shares":1154,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This restricted stock award was granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders."}],"balance_after":4682,"source":{"system":"sec-edgar","filing":"0001225208-25-004951","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520825004951/doc4.xml","form_type":"4"}},{"id":1154332,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-09T23:57:42.000Z","date":"2025-05-09","kind":"grant","planned":false,"acquired":true,"shares":3528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units were granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders."}],"balance_after":3528,"source":{"system":"sec-edgar","filing":"0001225208-25-004951","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520825004951/doc4.xml","form_type":"4"}},{"id":1503397,"issuer":{"id":4007,"kind":"organization","name":"Envista Holdings Corp"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-23T20:35:05.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":10085,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of an annual equity grant of Restricted Stock Units (\"RSUs\") for the Reporting Person's service as a director of the Issuer. The RSUs will vest one year after the grant date. RSUs are payable in shares of common stock on a one-to-one basis."}],"balance_after":34230,"source":{"system":"sec-edgar","filing":"0001757073-24-000055","document":"wk-form4_1716496479.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1308428/000175707324000055/wk-form4_1716496479.xml","form_type":"4"}},{"id":1522413,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-09T23:41:38.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This restricted stock award was granted on May 8, 2024 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders."}],"balance_after":4054,"source":{"system":"sec-edgar","filing":"0001225208-24-005893","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824005893/doc4.xml","form_type":"4"}},{"id":1522412,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-09T23:41:38.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":3055,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units were granted on May 8, 2024 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders."}],"balance_after":3055,"source":{"system":"sec-edgar","filing":"0001225208-24-005893","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824005893/doc4.xml","form_type":"4"}},{"id":1620417,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Director Stock Option (Right to Acquire)","published_at":"2024-02-26T22:52:21.000Z","date":"2024-02-23","kind":"exercise","planned":false,"acquired":false,"shares":7056,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":36.8633,"exercise_date":"2017-05-12","expiration_date":"2024-05-11","underlying":"Common Stock","underlying_shares":7056},"source":{"system":"sec-edgar","filing":"0001225208-24-002963","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824002963/doc4.xml","form_type":"4"}},{"id":1620416,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-02-26T22:52:21.000Z","date":"2024-02-23","kind":"sale","planned":false,"acquired":false,"shares":3058,"price":87.61,"value":267911.38,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $87.5908 to $87.6210. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":67219,"source":{"system":"sec-edgar","filing":"0001225208-24-002963","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824002963/doc4.xml","form_type":"4"}},{"id":1620415,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-02-26T22:52:21.000Z","date":"2024-02-23","kind":"gift","planned":false,"acquired":true,"shares":7056,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"balance_after":70277,"source":{"system":"sec-edgar","filing":"0001225208-24-002963","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824002963/doc4.xml","form_type":"4"}},{"id":1620414,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-02-26T22:52:21.000Z","date":"2024-02-23","kind":"gift","planned":false,"acquired":false,"shares":7056,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3701,"source":{"system":"sec-edgar","filing":"0001225208-24-002963","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824002963/doc4.xml","form_type":"4"}},{"id":1620413,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-02-26T22:52:21.000Z","date":"2024-02-23","kind":"exercise","planned":false,"acquired":true,"shares":7056,"price":36.8633,"value":260107.4448,"ownership":{"direct":true},"balance_after":10757,"source":{"system":"sec-edgar","filing":"0001225208-24-002963","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824002963/doc4.xml","form_type":"4"}},{"id":1877774,"issuer":{"id":4007,"kind":"organization","name":"Envista Holdings Corp"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-25T20:35:27.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":5425,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of an annual equity grant of Restricted Stock Units (\"RSUs\") for the Reporting Person's service as a director of the Issuer. The RSUs will vest one year after the grant date. RSUs are payable in shares of common stock on a one-to-one basis."}],"balance_after":24145,"source":{"system":"sec-edgar","filing":"0001757073-23-000047","document":"wf-form4_168504691499766.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1308428/000175707323000047/wf-form4_168504691499766.xml","form_type":"4"}},{"id":1894013,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-05-15T22:22:27.000Z","date":"2023-05-12","kind":"grant","planned":false,"acquired":true,"shares":898,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This restricted stock was granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders."}],"balance_after":3701,"source":{"system":"sec-edgar","filing":"0001225208-23-005906","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823005906/doc4.xml","form_type":"4"}},{"id":1894012,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-05-15T22:22:27.000Z","date":"2023-05-12","kind":"grant","planned":false,"acquired":true,"shares":2803,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units were granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders."}],"balance_after":2803,"source":{"system":"sec-edgar","filing":"0001225208-23-005906","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823005906/doc4.xml","form_type":"4"}},{"id":2251031,"issuer":{"id":4007,"kind":"organization","name":"Envista Holdings Corp"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-31T20:31:37.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":4435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of an annual equity grant of Restricted Stock Units (\"RSUs\") for the Reporting Person's service as a director of the Issuer. The RSUs will vest one year after the grant date. RSUs are payable in shares of common stock on a one-to-one basis."}],"balance_after":18720,"source":{"system":"sec-edgar","filing":"0001757073-22-000075","document":"wf-form4_165402905379209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1308428/000175707322000075/wf-form4_165402905379209.xml","form_type":"4"}},{"id":2270066,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-05-16T18:39:51.000Z","date":"2022-05-13","kind":"other","acquired":false,"shares":13248,"price":28.25,"value":374256.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":13.05,"expiration_date":"2027-01-17","underlying":"Common Stock","underlying_shares":13248},"source":{"system":"sec-edgar","filing":"0001562180-22-004073","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218022004073/primarydocument.xml","form_type":"4"}},{"id":2270065,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-05-16T18:39:51.000Z","date":"2022-05-13","kind":"other","acquired":false,"shares":25000,"price":28.25,"value":706250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":25.31,"expiration_date":"2025-04-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-22-004073","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218022004073/primarydocument.xml","form_type":"4"}},{"id":2270064,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-05-16T18:39:51.000Z","date":"2022-05-13","kind":"other","acquired":false,"shares":6035,"price":28.25,"value":170488.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":26.05,"expiration_date":"2027-05-31","underlying":"Common Stock","underlying_shares":6035},"source":{"system":"sec-edgar","filing":"0001562180-22-004073","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218022004073/primarydocument.xml","form_type":"4"}},{"id":2270063,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-05-16T18:39:51.000Z","date":"2022-05-13","kind":"other","acquired":false,"shares":3473,"price":28.25,"value":98112.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":42.05,"expiration_date":"2028-06-04","underlying":"Common Stock","underlying_shares":3473},"source":{"system":"sec-edgar","filing":"0001562180-22-004073","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218022004073/primarydocument.xml","form_type":"4"}},{"id":2270062,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-16T18:39:51.000Z","date":"2022-05-13","kind":"other","acquired":false,"shares":9666,"price":28.25,"value":273064.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":11.84,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":9666},"source":{"system":"sec-edgar","filing":"0001562180-22-004073","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218022004073/primarydocument.xml","form_type":"4"}},{"id":2270061,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-16T18:39:51.000Z","date":"2022-05-13","kind":"other","acquired":false,"shares":12500,"price":28.25,"value":353125.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":13.79,"expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001562180-22-004073","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218022004073/primarydocument.xml","form_type":"4"}},{"id":2270060,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-16T18:39:51.000Z","date":"2022-05-13","kind":"other","acquired":false,"shares":5734,"price":28.25,"value":161985.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":16.5,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":5734},"source":{"system":"sec-edgar","filing":"0001562180-22-004073","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218022004073/primarydocument.xml","form_type":"4"}},{"id":2270059,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-16T18:39:51.000Z","date":"2022-05-13","kind":"other","acquired":false,"shares":82387,"price":28.25,"value":2327432.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":17.01,"expiration_date":"2029-09-29","underlying":"Common Stock","underlying_shares":82387},"source":{"system":"sec-edgar","filing":"0001562180-22-004073","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218022004073/primarydocument.xml","form_type":"4"}},{"id":2270058,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-16T18:39:51.000Z","date":"2022-05-13","kind":"other","acquired":false,"shares":3390,"price":28.25,"value":95767.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":21,"expiration_date":"2031-03-15","underlying":"Common Stock","underlying_shares":3390},"source":{"system":"sec-edgar","filing":"0001562180-22-004073","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218022004073/primarydocument.xml","form_type":"4"}},{"id":2270057,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-16T18:39:51.000Z","date":"2022-05-13","kind":"other","acquired":false,"shares":120064,"price":28.25,"value":3391808.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":25.1,"expiration_date":"2029-05-06","underlying":"Common Stock","underlying_shares":120064},"source":{"system":"sec-edgar","filing":"0001562180-22-004073","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218022004073/primarydocument.xml","form_type":"4"}},{"id":2270056,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-16T18:39:51.000Z","date":"2022-05-13","kind":"other","acquired":false,"shares":29262,"price":28.25,"value":826651.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are held by the Gallahue Irrevocable Trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-22-004073","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218022004073/primarydocument.xml","form_type":"4"}},{"id":2270055,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-16T18:39:51.000Z","date":"2022-05-13","kind":"other","acquired":false,"shares":5011,"price":28.25,"value":141560.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-22-004073","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218022004073/primarydocument.xml","form_type":"4"}},{"id":2270054,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-16T18:39:51.000Z","date":"2022-05-13","kind":"other","acquired":false,"shares":3239,"price":28.25,"value":91501.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes."}],"balance_after":5011,"source":{"system":"sec-edgar","filing":"0001562180-22-004073","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218022004073/primarydocument.xml","form_type":"4"}},{"id":2276573,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-10T20:39:12.000Z","date":"2022-05-04","kind":"grant","acquired":true,"shares":737,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This restricted stock was granted on May 4, 2022 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders."}],"balance_after":3037,"source":{"system":"sec-edgar","filing":"0001225208-22-006786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822006786/doc4.xml","form_type":"4"}},{"id":2276572,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-10T20:39:12.000Z","date":"2022-05-04","kind":"grant","acquired":true,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units were granted on May 4, 2022 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders."}],"balance_after":2300,"source":{"system":"sec-edgar","filing":"0001225208-22-006786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822006786/doc4.xml","form_type":"4"}},{"id":2338202,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:23:59.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":7202,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":65.19,"underlying":"Common Stock","underlying_shares":7202},"source":{"system":"sec-edgar","filing":"0001628280-22-005915","document":"wf-form4_164703381927122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005915/wf-form4_164703381927122.xml","form_type":"4"}},{"id":2338201,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:23:59.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":61.31,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001628280-22-005915","document":"wf-form4_164703381927122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005915/wf-form4_164703381927122.xml","form_type":"4"}},{"id":2338200,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:23:59.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":56.5,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001628280-22-005915","document":"wf-form4_164703381927122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005915/wf-form4_164703381927122.xml","form_type":"4"}},{"id":2338199,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:23:59.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":4583,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":44.79,"underlying":"Common Stock","underlying_shares":4583},"source":{"system":"sec-edgar","filing":"0001628280-22-005915","document":"wf-form4_164703381927122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005915/wf-form4_164703381927122.xml","form_type":"4"}},{"id":2338198,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:23:59.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":44.79,"underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001628280-22-005915","document":"wf-form4_164703381927122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005915/wf-form4_164703381927122.xml","form_type":"4"}},{"id":2338197,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-11T16:23:59.000Z","date":"2022-03-11","kind":"other","acquired":false,"shares":8167,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an \"Issuer RSU\"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an \"Issuer RSU\"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-22-005915","document":"wf-form4_164703381927122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005915/wf-form4_164703381927122.xml","form_type":"4"}},{"id":2338196,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-11T16:23:59.000Z","date":"2022-03-11","kind":"other","acquired":false,"shares":1116,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. (\"Parent\") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger (the \"Merger\") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock, $0.0001 par value per share (\"Issuer Common Stock\"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the \"Merger Consideration\"), subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. (\"Parent\") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger (the \"Merger\") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock, $0.0001 par value per share (\"Issuer Common Stock\"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the \"Merger Consideration\"), subject to any required withholding of taxes."}],"balance_after":8167,"source":{"system":"sec-edgar","filing":"0001628280-22-005915","document":"wf-form4_164703381927122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005915/wf-form4_164703381927122.xml","form_type":"4"}},{"id":2338195,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-11T16:23:59.000Z","date":"2022-03-11","kind":"other","acquired":false,"shares":3628,"ownership":{"direct":false,"nature":"By The Gallahue Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. (\"Parent\") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger (the \"Merger\") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock, $0.0001 par value per share (\"Issuer Common Stock\"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the \"Merger Consideration\"), subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. (\"Parent\") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger (the \"Merger\") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock, $0.0001 par value per share (\"Issuer Common Stock\"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the \"Merger Consideration\"), subject to any required withholding of taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-22-005915","document":"wf-form4_164703381927122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005915/wf-form4_164703381927122.xml","form_type":"4"}},{"id":2408876,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Director Stock Option (Right to Acquire)","published_at":"2022-02-09T01:19:26.000Z","date":"2022-02-08","kind":"exercise","acquired":false,"shares":32256,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":22.2867,"exercise_date":"2016-02-19","expiration_date":"2022-02-18","underlying":"Common Stock","underlying_shares":32256},"source":{"system":"sec-edgar","filing":"0001225208-22-001657","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822001657/doc4.xml","form_type":"4"}},{"id":2408875,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-02-09T01:19:26.000Z","date":"2022-02-08","kind":"sale","acquired":false,"shares":32256,"price":110.7859,"value":3573509.9904,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $110.50 to $111.29. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3433,"source":{"system":"sec-edgar","filing":"0001225208-22-001657","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822001657/doc4.xml","form_type":"4"}},{"id":2408874,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-02-09T01:19:26.000Z","date":"2022-02-08","kind":"exercise","acquired":true,"shares":32256,"price":22.2867,"value":718879.7952,"ownership":{"direct":true},"balance_after":35689,"source":{"system":"sec-edgar","filing":"0001225208-22-001657","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822001657/doc4.xml","form_type":"4"}},{"id":2669044,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T17:27:12.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":7202,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 11, 2021 with the final installment vesting  upon the earlier of the one-year anniversary of the grant date or the date of the next annual stockholders' meeting, and are exercisable once vested."}],"balance_after":7202,"derivative":{"exercise_price":65.19,"expiration_date":"2028-06-11","underlying":"Common Stock","underlying_shares":7202},"source":{"system":"sec-edgar","filing":"0001628280-21-012283","document":"wf-form4_162379240554999.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828021012283/wf-form4_162379240554999.xml","form_type":"4"}},{"id":2669043,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T17:27:12.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":3067,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest in full on the earliest of June 11, 2022, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units."}],"balance_after":9283,"source":{"system":"sec-edgar","filing":"0001628280-21-012283","document":"wf-form4_162379240554999.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828021012283/wf-form4_162379240554999.xml","form_type":"4"}},{"id":2679064,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-07T20:39:57.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":5734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest in 12 equal monthly installments commencing on June 3, 2021."}],"balance_after":5734,"derivative":{"exercise_price":16.5,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":5734},"source":{"system":"sec-edgar","filing":"0001562180-21-004111","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218021004111/primarydocument.xml","form_type":"4"}},{"id":2679063,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-07T20:39:57.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":3239,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 3, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,239 restricted stock units."}],"balance_after":8250,"source":{"system":"sec-edgar","filing":"0001562180-21-004111","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218021004111/primarydocument.xml","form_type":"4"}},{"id":2692847,"issuer":{"id":4007,"kind":"organization","name":"Envista Holdings Corp"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-27T20:39:58.000Z","date":"2021-05-25","kind":"grant","acquired":true,"shares":4020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of an annual equity grant of Restricted Stock Units (\"RSUs\") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the date of the Issuer's 2022 Annual Meeting of Stockholders, but the underlying shares will not be issued until the earlier of the Reporting Person's death or the first day of the seventh month following the Reporting Person's retirement from the Board of Directors of the Issuer. RSUs are payable in shares of common stock on a one-to-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 10,265 RSUs that were previously reported in Table II."}],"balance_after":14285,"source":{"system":"sec-edgar","filing":"0001757073-21-000078","document":"wf-form4_162214788952614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1308428/000175707321000078/wf-form4_162214788952614.xml","form_type":"4"}},{"id":2723741,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-05-07T22:30:59.000Z","date":"2021-05-07","kind":"grant","acquired":true,"shares":818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This restricted stock was granted on May 5, 2021 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders."}],"balance_after":3433,"source":{"system":"sec-edgar","filing":"0001225208-21-007755","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520821007755/doc4.xml","form_type":"4"}},{"id":2723740,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-05-07T22:30:59.000Z","date":"2021-05-07","kind":"grant","acquired":true,"shares":2615,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units were granted on May 5, 2021 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on the Issuer's Board."}],"balance_after":2615,"source":{"system":"sec-edgar","filing":"0001225208-21-007755","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520821007755/doc4.xml","form_type":"4"}},{"id":2778874,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-03-18T19:32:33.000Z","date":"2021-03-16","kind":"grant","acquired":true,"shares":3390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2021."}],"balance_after":3390,"derivative":{"exercise_price":21,"expiration_date":"2031-03-15","underlying":"Common Stock","underlying_shares":3390},"source":{"system":"sec-edgar","filing":"0001562180-21-002360","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218021002360/primarydocument.xml","form_type":"4"}},{"id":2860138,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-16T18:18:24.000Z","date":"2020-12-21","kind":"gift","acquired":false,"shares":3628,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 21, 2020, the Reporting Person transferred 3,628 shares of the Issuer's common stock to a family trust of which the Reporting Person is a trustee."}],"balance_after":6216,"source":{"system":"sec-edgar","filing":"0001209191-21-010950","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121010950/doc5.xml","form_type":"5"}},{"id":3109523,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-16T19:42:58.000Z","date":"2020-06-12","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 12, 2020, and are exercisable once vested."}],"balance_after":5000,"derivative":{"exercise_price":61.31,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-20-037104","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120037104/doc4.xml","form_type":"4"}},{"id":3109522,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-16T19:42:58.000Z","date":"2020-06-12","kind":"grant","acquired":true,"shares":2446,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest in full on the earliest of June 12, 2021, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units."}],"balance_after":9844,"source":{"system":"sec-edgar","filing":"0001209191-20-037104","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120037104/doc4.xml","form_type":"4"}},{"id":3118420,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-08T16:49:56.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":9666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest in 12 equal monthly installments commencing on June 4, 2020."}],"balance_after":9666,"derivative":{"exercise_price":11.84,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":9666},"source":{"system":"sec-edgar","filing":"0001562180-20-004315","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218020004315/primarydocument.xml","form_type":"4"}},{"id":3118419,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-08T16:49:56.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":5011,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 4, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,011 restricted stock units."}],"balance_after":34273,"source":{"system":"sec-edgar","filing":"0001562180-20-004315","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218020004315/primarydocument.xml","form_type":"4"}},{"id":3130318,"issuer":{"id":4007,"kind":"organization","name":"Envista Holdings Corp"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2020-05-29T20:21:45.000Z","date":"2020-05-27","kind":"grant","acquired":true,"shares":8230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units are payable in shares of common stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units granted will vest on the date of the Issuer's 2021 annual meeting of stockholders, but the underlying shares will not be issued until the earlier of the Reporting Person's death or the first day of the seventh month following the Reporting Person's retirement from the Board of Directors of the issuer."}],"balance_after":8230,"derivative":{"expiration_date":"2030-05-26","underlying":"Common Stock","underlying_shares":8230},"source":{"system":"sec-edgar","filing":"0001415889-20-001372","document":"form4-05292020_010531.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1308428/000141588920001372/form4-05292020_010531.xml","form_type":"4"}},{"id":3155039,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-05-11T18:10:28.000Z","date":"2020-05-07","kind":"gift","acquired":true,"shares":1737,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"balance_after":17471,"source":{"system":"sec-edgar","filing":"0001225208-20-007361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520820007361/doc4.xml","form_type":"4"}},{"id":3155038,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-05-11T18:10:28.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":345,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This restricted stock was granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders."}],"balance_after":1446,"source":{"system":"sec-edgar","filing":"0001225208-20-007361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520820007361/doc4.xml","form_type":"4"}},{"id":3155037,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-05-11T18:10:28.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":1101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board."}],"balance_after":1101,"source":{"system":"sec-edgar","filing":"0001225208-20-007361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520820007361/doc4.xml","form_type":"4"}},{"id":3155036,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-05-11T18:10:28.000Z","date":"2020-05-07","kind":"gift","acquired":false,"shares":1737,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001225208-20-007361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520820007361/doc4.xml","form_type":"4"}},{"id":3333753,"issuer":{"id":4007,"kind":"organization","name":"Envista Holdings Corp"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-20T22:34:40.000Z","date":"2019-12-18","kind":"grant","acquired":true,"shares":2035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of restricted stock units under the Envista Holdings Corporation 2019 Omnibus Incentive Plan, which will vest on the earlier to occur of the first anniversary of the date of grant or the date of the Issuer's 2020 annual meeting of stockholders, subject to continued service through such date."}],"balance_after":2035,"source":{"system":"sec-edgar","filing":"0000899243-19-029795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1308428/000089924319029795/doc4.xml","form_type":"4"}},{"id":3400696,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2019-10-02T17:09:31.000Z","date":"2019-09-30","kind":"grant","acquired":true,"shares":82387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/8 of the shares subject to the option vest on September 30, 2019 and 1/8th of the shares subject to the option vests monthly on the last business day of the month thereafter over seven (7) successive months."}],"balance_after":82387,"derivative":{"exercise_price":17.01,"expiration_date":"2029-09-29","underlying":"Common Stock","underlying_shares":82387},"source":{"system":"sec-edgar","filing":"0001562180-19-005068","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218019005068/primarydocument.xml","form_type":"4"}},{"id":3400695,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2019-10-02T17:09:31.000Z","date":"2019-09-30","kind":"grant","acquired":true,"shares":17202,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. 100% of the restricted stock units shall vest on April 30, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 17,202 restricted stock units."}],"balance_after":29262,"source":{"system":"sec-edgar","filing":"0001562180-19-005068","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218019005068/primarydocument.xml","form_type":"4"}},{"id":3488357,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-17T18:43:13.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 13, 2019, and are exercisable once vested."}],"balance_after":5000,"derivative":{"exercise_price":56.5,"expiration_date":"2026-06-13","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-19-037490","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119037490/doc4.xml","form_type":"4"}},{"id":3488356,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-17T18:43:13.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":2654,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest in full on the earliest of June 13, 2020, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units."}],"balance_after":7398,"source":{"system":"sec-edgar","filing":"0001209191-19-037490","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119037490/doc4.xml","form_type":"4"}},{"id":3530307,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-05-13T22:34:17.000Z","date":"2019-05-09","kind":"grant","acquired":true,"shares":414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This restricted stock was granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested on March 15, 2020."}],"balance_after":1737,"source":{"system":"sec-edgar","filing":"0001225208-19-007857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520819007857/doc4.xml","form_type":"4"}},{"id":3530306,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-05-13T22:34:17.000Z","date":"2019-05-09","kind":"grant","acquired":true,"shares":1323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units were granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program.  They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders.  The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board."}],"balance_after":1323,"source":{"system":"sec-edgar","filing":"0001225208-19-007857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520819007857/doc4.xml","form_type":"4"}},{"id":3534974,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2019-05-08T18:45:39.000Z","date":"2019-05-07","kind":"grant","acquired":true,"shares":180096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in six equal monthly installments commencing on May 31, 2019."}],"balance_after":180096,"derivative":{"exercise_price":25.1,"expiration_date":"2029-05-06","underlying":"Common Stock","underlying_shares":180096},"source":{"system":"sec-edgar","filing":"0001562180-19-002724","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218019002724/primarydocument.xml","form_type":"4"}},{"id":3870638,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-07-10T16:14:14.000Z","date":"2018-07-06","kind":"grant","acquired":true,"shares":4583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on August 6, 2018, and are exercisable once vested."}],"balance_after":4583,"derivative":{"exercise_price":44.79,"expiration_date":"2025-07-06","underlying":"Common Stock","underlying_shares":4583},"source":{"system":"sec-edgar","filing":"0001209191-18-042143","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919118042143/doc4.xml","form_type":"4"}},{"id":3870637,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-07-10T16:14:14.000Z","date":"2018-07-06","kind":"grant","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in 36 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over three years beginning on August 6, 2018, and are exercisable once vested."}],"balance_after":2500,"derivative":{"exercise_price":44.79,"expiration_date":"2025-07-06","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-18-042143","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919118042143/doc4.xml","form_type":"4"}},{"id":3870636,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-10T16:14:14.000Z","date":"2018-07-06","kind":"grant","acquired":true,"shares":3070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The amount represents restricted stock units that vest in full on the earliest of June 13, 2019, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units."}],"balance_after":4744,"source":{"system":"sec-edgar","filing":"0001209191-18-042143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919118042143/doc4.xml","form_type":"4"}},{"id":3870635,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-10T16:14:14.000Z","date":"2018-07-06","kind":"grant","acquired":true,"shares":1674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest in three equal installments on the dates of Arena's next three annual meetings of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units."}],"balance_after":1674,"source":{"system":"sec-edgar","filing":"0001209191-18-042143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919118042143/doc4.xml","form_type":"4"}},{"id":3901417,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2018-06-07T17:20:46.000Z","date":"2018-06-05","kind":"grant","acquired":true,"shares":3473,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest in 12 equal monthly installments commencing on June 5, 2018."}],"balance_after":3473,"derivative":{"exercise_price":42.05,"expiration_date":"2028-06-04","underlying":"Common Stock","underlying_shares":3473},"source":{"system":"sec-edgar","filing":"0001562180-18-002920","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218018002920/primarydocument.xml","form_type":"4"}},{"id":3901416,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-07T17:20:46.000Z","date":"2018-06-05","kind":"grant","acquired":true,"shares":1514,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan.  Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting.  The restricted stock units vest one year from grant date on June 5, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,514 RSUs."}],"balance_after":12060,"source":{"system":"sec-edgar","filing":"0001562180-18-002920","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218018002920/primarydocument.xml","form_type":"4"}},{"id":3922584,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-05-23T00:00:44.000Z","date":"2018-05-12","kind":"gift","acquired":true,"shares":2034,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"balance_after":13600,"source":{"system":"sec-edgar","filing":"0001225208-18-009759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520818009759/doc4.xml","form_type":"4"}},{"id":3922583,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-05-23T00:00:44.000Z","date":"2018-05-18","kind":"grant","acquired":true,"shares":479,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This restricted stock was granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders."}],"balance_after":2134,"source":{"system":"sec-edgar","filing":"0001225208-18-009759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520818009759/doc4.xml","form_type":"4"}},{"id":3922582,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-05-23T00:00:44.000Z","date":"2018-05-18","kind":"grant","acquired":true,"shares":1655,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program.  They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board."}],"balance_after":1655,"source":{"system":"sec-edgar","filing":"0001225208-18-009759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520818009759/doc4.xml","form_type":"4"}},{"id":3922581,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-05-23T00:00:44.000Z","date":"2018-05-12","kind":"gift","acquired":false,"shares":2034,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001225208-18-009759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520818009759/doc4.xml","form_type":"4"}},{"id":4292626,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2017-06-05T19:29:24.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":6035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest in 12 equal monthly installments commencing on June 1, 2017."}],"balance_after":6035,"derivative":{"exercise_price":26.05,"expiration_date":"2027-05-31","underlying":"Common Stock","underlying_shares":6035},"source":{"system":"sec-edgar","filing":"0001562180-17-002197","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218017002197/primarydocument.xml","form_type":"4"}},{"id":4292625,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-05T19:29:24.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":2546,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan.  Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting.  The restricted stock units vest one year from grant date on June 1, 2018."}],"balance_after":10546,"source":{"system":"sec-edgar","filing":"0001562180-17-002197","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218017002197/primarydocument.xml","form_type":"4"}},{"id":4321437,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Director Stock Option (Right to Acquire)","published_at":"2017-05-15T21:21:38.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":2352,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options were granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person."}],"balance_after":2352,"derivative":{"exercise_price":110.59,"exercise_date":"2017-05-12","expiration_date":"2024-05-11","underlying":"Common Stock","underlying_shares":2352},"source":{"system":"sec-edgar","filing":"0001225208-17-009784","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520817009784/doc4.xml","form_type":"4"}},{"id":4321436,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-05-15T21:21:38.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":2034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units were granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program.  They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person; and it reflects 2,524 shares that were previously reported as directly held."}],"balance_after":2034,"source":{"system":"sec-edgar","filing":"0001225208-17-009784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520817009784/doc4.xml","form_type":"4"}},{"id":4466740,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-02-06T22:31:45.000Z","date":"2017-02-03","kind":"purchase","acquired":true,"shares":3000,"price":90.1,"value":270300.0,"ownership":{"direct":false,"nature":"By Trust"},"balance_after":9042,"source":{"system":"sec-edgar","filing":"0001225208-17-002461","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520817002461/doc4.xml","form_type":"4"}},{"id":4485112,"issuer":{"id":127294,"kind":"organization","name":"Intersect ENT, Inc.","symbol":"XENT"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2017-01-20T19:36:39.000Z","date":"2017-01-18","kind":"grant","acquired":true,"shares":13248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2017."}],"balance_after":13248,"derivative":{"exercise_price":13.05,"expiration_date":"2027-01-17","underlying":"Common Stock","underlying_shares":13248},"source":{"system":"sec-edgar","filing":"0001562180-17-000293","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271214/000156218017000293/primarydocument.xml","form_type":"4"}},{"id":4537514,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":45155,"kind":"person","name":"GALLAHUE KIERAN","position":1,"cik":"0001308428","reported_name":"GALLAHUE KIERAN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2016-12-02T00:18:43.000Z","date":"2016-11-29","kind":"purchase","acquired":true,"shares":3000,"price":84.6334,"value":253900.2,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $84.38 to $84.98.  The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a difference of 3,042 shares which were previously reported as directly held by the Reporting Person but are held by Trust. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person."}],"balance_after":6042,"source":{"system":"sec-edgar","filing":"0001225208-16-042548","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520816042548/doc4.xml","form_type":"4"}}]}